|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus 显示文摘 | Koherman OG Kim DD Shen L Ruggles JA Nielsen LL Fineman MS | 2005 | Am J Health Syst Pharm2005，62，2： | 1 |
| 2 | Synthetic ex- endin- 4 ( AC2993 ) significantly reducespostprandial and fasting plasma glucose in subjects with type 2 diabetes 显示文摘 | Koherman OG Buse JB Fineman MS | 2003 | Clin Endocrinol Metab2003，88，7： | 1 |
| 3 | Pharmacokineties, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus显示文摘 | Koherman OG Kim DD Shen L | 2005 | Am J Health Syst Pharm2005，62，2： | 1 |
| 4 | Pharmacokincties, pharma-codyna, and safety of exenatide in patients with type 2 diabetes mellitus显示文摘 | Koherman OG Kim DD Shen L | 2005 | Am J Health Syst Pharm2005，62，： | 1 |
| 5 | Pharmaeokineties,pharmacodynamics,and safety of exenatide in patients with type 2 diabetes mellitus显示文摘 | Koherman OG Kim DD Shen L | 2005 | Am J Health Syst Pharm2005，62，2： | 1 |
| 6 | Pharmacokinetics and pharmacodynamics,and safety of exenatide in patients with type 2 diabetes mellitus 显示文摘 | Koherman OG Kim DD Shen L | 2005 | Amercan J Health-System Pharmacy2005，62，2： | 1 |
| 7 | Mechanisms of insulin resistance in human obesity : evidence for receptor and postreceptor defects显示文摘 | Koherman OG Insel J Saekow M | 1980 | J Clin Invest1980，65，： | 1 |
| 8 | Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus 显示文摘 | Koherman OG Kim DD Shen L | 2005 | Am J Health Syst Pharm2005，62，2： | 1 |
| 9 | Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus 显示文摘 | Koherman OG Gray RS Griffin J | 1981 | J Clin Invest1981，68，4： | 1 |
| 10 | Pharmacokinetics,pharma- codynamics, and safety of exenatide in patients with type 2 diabetes mellitus显示文摘 | Koherman OG Kim DD Shen L | 2005 | Am J Health - Syst Ph2005，62，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员